Evidence map›Paper›PMID 34850892›Full record

ArticleThe Journal of infectious diseases2023

Gene Expression Risk Scores for COVID-19 Illness Severity.

Derick R Peterson, Andrea M Baran, Soumyaroop Bhattacharya, Angela R Branche, Daniel P Croft, Anthony M Corbett, Edward E Walsh, Ann R Falsey, Thomas J Mariani

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Role ofSaudi journal of biological sciences · 2023
    Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Derick R PetersonDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
Andrea M BaranDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
Soumyaroop BhattacharyaDivision of Neonatology and Pediatric Molecular and Personalized Medicine Program, Department of Pediatrics, University of Rochester, Rochester, New York, USA.ORCID 0000-0003-1140-7845
Angela R BrancheDivision of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, New York, USA.
Daniel P CroftDivision of Pulmonary and Critical Care, Department of Medicine, University of Rochester, Rochester, New York, USA.
Anthony M CorbettDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
Edward E WalshDivision of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, New York, USA.
Ann R FalseyDivision of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, New York, USA.
Thomas J MarianiDivision of Neonatology and Pediatric Molecular and Personalized Medicine Program, Department of Pediatrics, University of Rochester, Rochester, New York, USA.
University of Rochester · USRochester General Hospital · US

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Martha Susiarjo · 1985 to 2026
$42.8M
The University of Rochester's Clinical and Translational Science InstituteUL1TR002001 · NCATS · UNIVERSITY OF ROCHESTER · PI WILSON, KAREN M., ZAND, MARTIN S · 2016 to 2024
$34.6M
Transcriptional Profiling to Discriminate Bacterial and Non-bacterial Respiratory IllnessesR01AI137364 · NIAID · UNIVERSITY OF ROCHESTER · PI FALSEY, ANN R, MARIANI, THOMAS J · 2019 to 2023
$3.8M
Effect of Air Pollution on the Immune Response to Respiratory Viral Infection in AdultsK23ES032459 · NIEHS · UNIVERSITY OF ROCHESTER · PI CROFT, DANIEL PATRICK · 2021 to 2025
$1.2M
NCATS NIH HHS UL1 TR002001NIAID NIH HHS R01 AI137364NIEHS NIH HHS K23 ES032459NIEHS NIH HHS P30 ES001247NIH HHS AI137364
6 · The paper itself

Abstract

backgroundThe correlates of coronavirus disease 2019 (COVID-19) illness severity following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are incompletely understood.

methodsWe assessed peripheral blood gene expression in 53 adults with confirmed SARS-CoV-2 infection clinically adjudicated as having mild, moderate, or severe disease. Supervised principal components analysis was used to build a weighted gene expression risk score (WGERS) to discriminate between severe and nonsevere COVID-19.

resultsGene expression patterns in participants with mild and moderate illness were similar, but significantly different from severe illness. When comparing severe versus nonsevere illness, we identified >4000 genes differentially expressed (false discovery rate < 0.05). Biological pathways increased in severe COVID-19 were associated with platelet activation and coagulation, and those significantly decreased with T-cell signaling and differentiation. A WGERS based on 18 genes distinguished severe illness in our training cohort (cross-validated receiver operating characteristic-area under the curve [ROC-AUC] = 0.98), and need for intensive care in an independent cohort (ROC-AUC = 0.85). Dichotomizing the WGERS yielded 100% sensitivity and 85% specificity for classifying severe illness in our training cohort, and 84% sensitivity and 74% specificity for defining the need for intensive care in the validation cohort.

conclusionsThese data suggest that gene expression classifiers may provide clinical utility as predictors of COVID-19 illness severity.

Indexed as

COVID-19AdultGene ExpressionHumansPatient AcuityRetrospective StudiesRisk FactorsSARS-CoV-2Severity of Illness IndexCOVID-19ICUmolecular markerspredictionRNA sequencingseverity

Identifiers

PMID34850892
PMCPMC8767880
OpenAlexW3215164406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.